Low-Dose Decitabine-Based Chemoimmunotherapy for Patients with Refractory Advanced Solid Tumors: A Phase I/II Report

Table 5

Baseline diagnosis of patients whose PFS was significantly prolonged compared to their previous PFS.

	𝑛	Baseline diagnosis
DAC	2	Hepatocellular carcinoma
		Esophageal adenocarcinoma
DAC + chemo	10	Hodgkin’s lymphoma (3)
		Respiratory tract cancer (2)
		Lung adenocarcinoma (2)
		Urogenital neoplasms (3)
DAC + CIK	3	Pancreatic cancer
		Hepatocellular carcinoma (2)

Note. CIK: cytokine induced killer cells; DAC + chemo: decitabine in combination with chemotherapy; DAC + CIK: decitabine in combination with CIK. 𝑃 value < 0.05 was considered significant.